Trevi Therapeutics Inc [TRVI] stock is trading at $3.35, up 7.37%. An important factor to consider is whether the stock is rising or falling in short-term value. The TRVI shares have gain 5.35% over the last week, with a monthly amount drifted -2.62%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Raymond James started tracking the stock with Outperform rating on August 30, 2024, and set its price target to $9. On August 30, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $6 on the stock. Rodman & Renshaw started tracking the stock assigning a Buy rating and suggested a price target of $7 on June 13, 2024. B. Riley Securities initiated its recommendation with a Buy and recommended $6 as its price target on April 12, 2023. SVB Leerink started tracking with a Outperform rating for this stock on November 22, 2022, and assigned it a price target of $6. In a note dated June 03, 2019, SVB Leerink initiated an Outperform rating and provided a target price of $14 on this stock.
Trevi Therapeutics Inc [TRVI] stock has fluctuated between $0.97 and $4.00 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Trevi Therapeutics Inc [NASDAQ: TRVI] shares were valued at $3.35 at the most recent close of the market. An investor can expect a potential return of 168.66% based on the average TRVI price forecast.
Analyzing the TRVI fundamentals
Gross Profit Margin for this corporation currently stands at 0.19% with Operating Profit Margin at -245.3%, Pretax Profit Margin comes in at -220.36%, and Net Profit Margin reading is -220.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -0.5 and Total Capital is -0.64. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.19 points at the first support level, and at 3.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.47, and for the 2nd resistance point, it is at 3.60.
Ratios To Look Out For
For context, Trevi Therapeutics Inc’s Current Ratio is 10.68. On the other hand, the Quick Ratio is 10.68, and the Cash Ratio is 1.92.
Transactions by insiders
Recent insider trading involved GOOD JENNIFER L, President & CEO, that happened on Sep 06 ’24 when 4219.0 shares were sold. President & CEO, GOOD JENNIFER L completed a deal on Sep 09 ’24 to sell 1840.0 shares. Meanwhile, President & CEO GOOD JENNIFER L sold 40277.0 shares on Sep 05 ’24.
